Exelixis, Inc. (Nasdaq: EXEL) announced results from a phase 1 trial of cabozantinib in combination with nivolumab in patients with ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

Piper Jaffray Upgrades Exelixis (EXEL) to OverweightOctober 10, 2016 9:09 AM Genentech (RHHBY) Announces Significant Data from TECENTRIQ Phase 3 Data in Specific Lung CancerOctober 10, 2016 6:29 AM Exelixis (EXEL) Announces Presentation of Cobimetinib, Vemurafenib, Atezolizumab Combo Phase 1b Data in BRAF V600October 7, 2016 7:38 AM Exelixis Announces Phase 1 Trial Results for Cabozantinib in Combination with Nivolumab in Advanced Genitourinary TumorsOctober 7, 2016 4:00 AM